Milland
Diamond
- Joined
- Jul 6, 2006
- Location
- Hillsboro, New Hampshire
The Chinese vaccine from Sinovac seems to have lower effectiveness than originally claimed, at around 50%. This is close to being considered "ineffective" by medical standards:
China's Sinovac vaccine trial results far less effective than initially claimed in Brazil - CNN
Another CN jab from Sinopharm (would a cold medicine be SinoSino?) seems better at nearly 80%, but along with the AstraZeneca product being 70%, it shows there's a large disparity to the two American (yes, one is really German) shots which are about 95% effective.
If I were advising Biden, I'd suggest that there be a way to (with appropriate quality control) "lease" the formulas to other countries/companies for broad-scale production.
The "brew" is likely replicable by most modern production facilities, which means manufacture of the best vaccines could be massively increased, giving a chance at faster treatments around the world.
I suspect the biggest stumbling blocks would be the refrigeration requirements during production and distribution, including the lab-lines themselves. So that might mean the Moderna vaccine takes priority, as its formulation allows it to work at "higher cold" temps.
Yes, there's doubtless protected technology and financial reward issues that would need to be factored in, but this is literally a world-wide crisis, and I think such things could be worked out after the fact if needed.
But what a way to repair some of the loss of status we've suffered in the last four years. If nothing else, the diplomatic value is incalculable. And that's soft power, don't knock how much it matters in global negotiations.
China's Sinovac vaccine trial results far less effective than initially claimed in Brazil - CNN
Another CN jab from Sinopharm (would a cold medicine be SinoSino?) seems better at nearly 80%, but along with the AstraZeneca product being 70%, it shows there's a large disparity to the two American (yes, one is really German) shots which are about 95% effective.
If I were advising Biden, I'd suggest that there be a way to (with appropriate quality control) "lease" the formulas to other countries/companies for broad-scale production.
The "brew" is likely replicable by most modern production facilities, which means manufacture of the best vaccines could be massively increased, giving a chance at faster treatments around the world.
I suspect the biggest stumbling blocks would be the refrigeration requirements during production and distribution, including the lab-lines themselves. So that might mean the Moderna vaccine takes priority, as its formulation allows it to work at "higher cold" temps.
Yes, there's doubtless protected technology and financial reward issues that would need to be factored in, but this is literally a world-wide crisis, and I think such things could be worked out after the fact if needed.
But what a way to repair some of the loss of status we've suffered in the last four years. If nothing else, the diplomatic value is incalculable. And that's soft power, don't knock how much it matters in global negotiations.